IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS ‐Dependent IFN Production and Cuproptosis Activation
Genes, Chromosomes and Cancer · 2026
DOI: 10.1002/gcc.70172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2026. Verfasst von Li Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cuproptosis, Interferon Regulatory Factors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Chengdu Medical Research Project, National Inheritance Studio for Famous & Senior Experts of Traditional Chinese Medicine.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. Cuproptosis is a novel form of regulated cell death closely linked to tumor progression. Although interferon regulatory factors (IRFs) exert tumor‐suppressive effects in various cancers, its precise regulatory mechanisms concerning cuproptosis in HCC remain largely elusive.
Methods
IRF8 expression was evaluated in clinical HCC specimens and cell lines. Gain‐ and loss‐of‐function assays were conducted. Underlying transcriptional mechanisms were elucidated using ChIP‐qPCR and dual‐luciferase reporter assays. Subcutaneous nude mouse xenograft models were utilized to validate in vivo phenotypes.
Results
IRF8 was significantly downregulated in HCC. IRF8 overexpression induced oxidative stress and cuproptosis, as evidenced by excessive intracellular copper accumulation, elevated reactive oxygen species (ROS), and lipid peroxidation. Mechanistically, IRF8 directly bound to the promoter region of lipoyl synthase (LIAS) to activate its transcription. Phenotypic rescue assays confirmed that LIAS is indispensable for IRF8‐induced interferon (IFN‐α/β) production, copper engorgement, and cuproptosis. Furthermore, in vivo xenograft models demonstrated that IRF8 profoundly impeded tumor growth, an effect that was effectively abrogated by LIAS silencing.
Conclusion
IRF8 inhibits HCC progression by directly upregulating LIAS to instigate lethal cuproptosis and interferon responses. The IRF8/LIAS axis may serve as a potential mechanistic basis and candidate axis for developing HCC therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Hepatology, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
- Xiamen AMOYTOP Biotech Co, Ltd., Xiamen, People's Republic of China.
- Department of Integrated Traditional Chinese and Western Medicine, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
- Center for Precision and Translational Medicine, Chengdu Public Health Clinical Center, Chengdu, People's Republic of China.
ORCID-Profile: Mei Luo
Förderung
- Chengdu Medical Research Project
- National Inheritance Studio for Famous & Senior Experts of Traditional Chinese Medicine
Zitieren
APA
Zhu, L., Hu, Z., Wu, B., Duan, M., Wang, L., Hu, R., Liao, H., Zhao, X., Zeng, Y., Li, L., Wang, Y., & Luo, M. (2026). IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS ‐Dependent IFN Production and Cuproptosis Activation. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70172
Vancouver
Zhu L, Hu Z, Wu B, Duan M, Wang L, Hu R, et al. IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS ‐Dependent IFN Production and Cuproptosis Activation. Genes, Chromosomes and Cancer. 2026. doi:10.1002/gcc.70172
BibTeX
@article{Zhu2026,
author = {Zhu, Li and Hu, Zhaoxia and Wu, Bei and Duan, Meng and Wang, Li and Hu, Ruiqing and Liao, Hongfan and Zhao, Xiaosi and Zeng, Yilan and Li, Lei and Wang, Yuelian and Luo, Mei},
title = {IRF8 Suppresses Hepatocellular Carcinoma Progression Through LIAS ‐Dependent IFN Production and Cuproptosis Activation},
journal = {Genes, Chromosomes and Cancer},
year = {2026},
doi = {10.1002/gcc.70172}
}
EUVIMED